Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07106021 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
A Phase 1 study of Idiopathic Parkinson´s Disease and Parkinson's Disease, sponsored by Kenai Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT07106021: Recruiting Phase 1 study of Idiopathic Parkinson´s Disease and Parkinson's Disease, sponsored by Kenai Therapeutics.
NCT07106021 is a Phase 1 study of Idiopathic Parkinson´s Disease and Parkinson's Disease that is actively recruiting participants, run by Kenai Therapeutics. The registered enrollment target is 12 participants, below the 218-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07106021, a Phase 1 study of Idiopathic Parkinson´s Disease and Parkinson's Disease, is actively recruiting participants, sponsored by Kenai Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.
Primary Outcome
The incidence of adverse events (AEs), serious AEs, AEs of special interest, and patient withdrawals
Conditions Studied
Interventions
- BIOLOGICAL RNDP-001
- DEVICE Syringe Front-Loading Device
Study Locations (3)
Arizona
- University of Arizona - Tucson
California
- Keck Medical Center of University of Southern California - Los Angeles
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-07-17 |
| Est. Completion | 2031-06 |
| Phase | Phase 1 |
What NCT07106021 shows while recruiting
NCT07106021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 218-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Idiopathic Parkinson´s Disease appearing as the primary indexed condition, and to 2 interventions - of which RNDP-001 is the first listed.
NCT07106021 reports a single indexed study location in Arizona, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT07106021 about?
NCT07106021 is a clinical study titled "A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease". This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.
What is the current status of trial NCT07106021?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-07-17. Estimated completion is 2031-06.
What conditions does trial NCT07106021 study?
This clinical trial studies the following conditions: Idiopathic Parkinson´s Disease, Parkinson's Disease.
What interventions are being tested in trial NCT07106021?
The interventions under investigation include: RNDP-001 (BIOLOGICAL), Syringe Front-Loading Device (DEVICE).
Who is sponsoring clinical trial NCT07106021?
This trial is sponsored by Kenai Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07106021 being conducted?
This trial has 3 study locations across Arizona, California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Parkinson´s Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Infusion of Apomorphine: Long-term Safety Study
ACTIVE NOT RECRUITING · Phase 3
-
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
COMPLETED · Phase 3
-
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
COMPLETED · Phase 3
-
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI